Latest SEC filings for Vertex Pharmaceuticals Incorporated (VRTX) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). All data sourced directly from SEC EDGAR — last updated 2026-07-23.
Tatsis Ourania (EVP, Chief Reg. & Quality Off.) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Sachdev Amit (EVP Chief Patient & Ext Af Off) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
SACHS BRUCE I (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Garber Alan M (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Tatsis Ourania, listed as EVP, Chief Reg. & Quality Off. at VERTEX PHARMACEUTICALS INC / MA, reported an open-market sale of 1,500 VRTX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
McKechnie Duncan, listed as EVP, Chief Commercial Officer at VERTEX PHARMACEUTICALS INC / MA, reported an open-market sale of 1,541 VRTX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
VERTEX PHARMACEUTICALS INC / MA filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer
Liu Joy, listed as EVP and Chief Legal Officer at VERTEX PHARMACEUTICALS INC / MA, reported an open-market sale of 828 VRTX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Tatsis Ourania filed a Form 144 with the SEC indicating intent to sell VRTX (VERTEX PHARMACEUTICALS INC / MA) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
McKechnie Duncan filed a Form 144 with the SEC indicating intent to sell VRTX (VERTEX PHARMACEUTICALS INC / MA) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
Liu Joy filed a Form 144 with the SEC indicating intent to sell VRTX (VERTEX PHARMACEUTICALS INC / MA) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
Bozic Carmen, listed as EVP and CMO at VERTEX PHARMACEUTICALS INC / MA, reported an open-market sale of 596 VRTX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Bozic Carmen filed a Form 144 with the SEC indicating intent to sell VRTX (VERTEX PHARMACEUTICALS INC / MA) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
Bozic Carmen, listed as EVP and CMO at VERTEX PHARMACEUTICALS INC / MA, reported an open-market sale of 1,020 VRTX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Bozic Carmen filed a Form 144 with the SEC indicating intent to sell VRTX (VERTEX PHARMACEUTICALS INC / MA) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
Bozic Carmen, listed as EVP and CMO at VERTEX PHARMACEUTICALS INC / MA, reported an open-market sale of 4,062 VRTX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Bozic Carmen filed a Form 144 with the SEC indicating intent to sell VRTX (VERTEX PHARMACEUTICALS INC / MA) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
Bozic Carmen, listed as EVP and CMO at VERTEX PHARMACEUTICALS INC / MA, reported an open-market sale of 1,745 VRTX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Bozic Carmen filed a Form 144 with the SEC indicating intent to sell VRTX (VERTEX PHARMACEUTICALS INC / MA) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
Liu Joy, listed as EVP and Chief Legal Officer at VERTEX PHARMACEUTICALS INC / MA, reported an open-market sale of 828 VRTX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Executives, directors, and large shareholders must report any purchase or sale of VRTX shares within two business days. Consistent buying by multiple insiders is often read as a confidence signal; large sales may reflect diversification or liquidity needs rather than negative conviction.
Filed when a company affiliate intends to sell restricted or control shares. A Form 144 is a notice of intent, not confirmation — the actual sale is later confirmed via Form 4. It gives investors advance visibility into planned insider selling activity.
The 8-K is an event-driven filing that Vertex Pharmaceuticals Incorporated must submit within four business days of a significant development — including earnings results, mergers, executive changes, credit facility updates, or regulatory actions. Each 8-K item code maps to a specific event type.
The 10-Q (quarterly) and 10-K (annual) are comprehensive reports covering Vertex Pharmaceuticals Incorporated's financial results, risk factors, management discussion, and business operations. The 10-K includes audited financials and is the most complete public disclosure the company makes each year.
View valuation, growth metrics, AI Strong Buy score, demand zones, peer comparison, and more — all on the VRTX stock analysis page.